secwatch.observer — SEC 8-K summary
======================================

Issuer:     Renalytix plc (RNLXY)
CIK:        0001811115
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0000950170-24-015596
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Renalytix Q2 FY2024 revenue $0.7M, net loss $8.5M; CMS sets $950/test
---------------------------------------------------------------------

- Revenue $0.7M from KidneyIntelX (down from $1.0M YoY); no pharma services revenue.
- Net loss improved to $8.5M from $10.4M YoY; cash & equivalents $5.6M at Dec 31, 2023.
- CMS finalized $950/test lab fee for kidneyintelX.dkd; NGS resumed claim payment.
- Targeting ~33% lower cash burn in Q3 FY2024 vs Q2; annualized burn under $23M.
- Published real-world evidence: 61% increase in kidney protective drug prescriptions after testing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024015596/0000950170-24-015596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811115/000095017024015596/rnlx-20240215.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-015596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer